Updated results of the global phase III ALEX trial comparing alectinib with crizotinib as first-line treatment against ALK-positive non-small cell
Continue reading »Home ยป
Two studies find resistance mechanisms in ALK+ and ROS1+ cancers
Targeted treatments have revolutionized care for lung cancer patients whose tumors harbor ALK or ROS1 alterations. Basically, cancers may use
Continue reading »